Material benefits:
1. Approval of Eisai's drug (more convincing than Aduhelm) will catalyse further investment in clinical research for Alzheimer's and other forms of dementia = benefit for CGS's clinical trials business.
2. Approval of Eisai's drug will generate a heightened need for cognitive assessment for diagnosis and ongoing monitoring of patients on drug = huge uplift for CGS's healthcare business.
What the hell just happened?, page-18
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CGS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
86.5¢ |
Change
0.015(1.76%) |
Mkt cap ! $147.7M | |||
| Open | High | Low | Value | Volume |
| 82.5¢ | 89.0¢ | 82.0¢ | $695.3K | 832.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 35086 | 82.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 89.0¢ | 1612 | 2 |
View Market Depth
| Last trade - 15.49pm 06/09/2024 (20 minute delay) ? |
| CGS (ASX) Chart |